Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor-Reference-Cited by-同舟云学术

Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor

Published:2019-05 Issue: Volume:449 Page:45-55
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Ahmed Kamal,Koval Alexey,Xu Jiabin,Bodmer Alexandre,Katanaev Vladimir L.^ORCID

Funder

Swiss Cancer League

Novartis Foundation for Medical-Biological Research

Stiftung zur Krebsbekämpfung

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference69 articles.

1. Wnt/beta-catenin signaling and disease;Clevers;Cell,2012

2. Wnt/beta-Catenin signaling, disease, and emerging therapeutic modalities;Nusse;Cell,2017

3. Targeting the Wnt pathways for therapies;Blagodatski;Mol. Cell. Ther.,2014

4. Can we safely target the WNT pathway?;Kahn;Nat. Rev. Drug Discov.,2014

5. Antimycobacterial activities of riminophenazines;Reddy;J. Antimicrob. Chemother.,1999

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. H3K27ac-induced RHOXF2 activates Wnt2/β-catenin pathway by binding to HOXC13 to aggravate the malignant progression of triple negative breast cancer;Cellular Signalling;2024-08

2. Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential;Heliyon;2024-08

3. Drug repurposing: a retrospective revolution in breast cancer medicine;Discover Medicine;2024-07-12

4. Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk;Gene;2024-07

5. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer;BMC Women's Health;2024-01-02